At this year’s European School of Haematology (ESH) ‘2nd How to Diagnose and Treat: Lymphoma’ conference, the Lymphoma Hub was proud to host a virtual Satellite Symposium on the management and treatment of patients with relapsed/refractory (R/R) lymphoma. Kieron Dunleavy, George Washington University Cancer Center, Washington, US, summarizes what he considers to be the feasible next steps for a patient with diffuse large B-cell lymphoma (DLBCL) following relapse to chimeric antigen receptor (CAR) T-cell therapy.